Industry News

28 Jan

CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia

MBX-8025 Produced Decreases of up to 45% in LDL-C Levels in a Genetic Rabbit Model of Homozygous Familial Hypercholesterolemia CymaBay Therapeutics (CBAY) today announced results from a preclinical study indicating the potential for MBX-8025 to decrease low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). MBX-8025 is...

Read more

28 Jan

Actinium to Participate in the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on February 3rd

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)(“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Mr. Sandesh Seth, Executive Chairman of Actinium, and other members of the management team will be attending the Canaccord Genuity Rare Disease and...

Read more

27 Jan

InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015

The New CGuard™ RX Rapid Exchange System Receives CE Mark Approval Six-Month Ultrasound Analysis Confirms Widely Patent Internal and External Carotid Arteries When Compared to Conventional Carotid Stents. InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it received...

Read more

23 Jan

GeoVax Provides Progress Report on its Ebola Vaccine Program

Ebola Vaccine Demonstrates Production of Virus-Like Particles in Human Cells ATLANTA, GA, January 12, 2015 – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.   In October 2014,...

Read more

21 Jan

Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET

Presentation to Discuss Capricor’s Duchenne Muscular Dystrophy Clinical Program LOS ANGELES, Jan. 21, 2015 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular...

Read more

20 Jan

Prima BioMed Receives $777K R&D Tax Incentive Refund

Prima BioMed Ltd (NASDAQ: PBMD) (ASX:PRR) (“Prima”) is pleased to advise that it has received approximately $777k in a cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate was provided essentially in respect of expenditures incurred on eligible Australian R&D activities conducted on the...

Read more

Page 215 of 256« First...102030...213214215216217...220230240...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets


Follow this blog

Get every new post delivered right to your inbox.

Email address